You are here:

1. Homepage
2. Pharmacovigilance
3. Information on Risks

Dear Doctor Letter (Rote-Hand-Brief) on Gilenya^® (fingolimod): Update on the recommendation for cardiovascular monitoring at the beginning of treatment

Important additional recommendations regarding a more intense monitoring of cardiovascular functions at the beginning of treatment with Gilenya^® (fingolimod) in patients with relapsing-remitting multiple sclerosis. A  Rote-Hand-Brief on Gilenya® (file size: 352 KB) will be circulated.